Cagrilintide FAQ: Your Questions Answered
The questions below are the ones that come up specifically about Cagrilintide, rather than general peptide questions that apply to everything.
Overview
Common questions: what amylin actually is, why a long-acting version was hard to make, how it differs from pramlintide, whether it works on the same targets as a GLP-1 molecule (it does not), and what a certificate of analysis should show.
What Cagrilintide actually is
Cagrilintide is an engineered copy of amylin — a hormone released from the pancreas at the same time as insulin. The natural version has a well-known problem: it clumps into fibres very readily, which is why nobody could make a long-lasting version of it for years. Cagrilintide is that problem solved, with six changes to the sequence and a fatty chain attached to make it last about a week instead of half an hour.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
Cagrilintide — common questions
What is cagrilintide an analogue of?
Human amylin, also called IAPP — a 37-residue hormone released from pancreatic beta cells alongside insulin. Cagrilintide keeps the 37-residue length, the Cys2–Cys7 disulfide and the amidated C-terminus, and changes six positions. Novo Nordisk describes it as having roughly 84% homology to native human amylin.
Why was a long-acting amylin analogue hard to make?
Because native amylin is one of the more amyloidogenic peptides known — its natural tendency is to convert from helix to beta-sheet and assemble into fibrils. Any analogue intended to persist for days has to resist that pathway for days. The published design answer was a helix-stabilising Glu14–Arg17 salt bridge plus proline substitutions in the C-terminal region to disfavour beta-sheet formation.
How does cagrilintide differ from pramlintide?
Pramlintide is the earlier, short-acting amylin analogue, sharing the three proline substitutions at positions 25, 28 and 29. Cagrilintide adds N14E, V17R and a C-terminal proline, and is acylated with a C20 fatty diacid for albumin binding. The practical difference is duration: pramlintide’s reported half-life is on the order of 20–45 minutes, cagrilintide’s roughly 174–186 hours.
Does it act on the same receptors as a GLP-1 agonist?
No. GLP-1 and GIP agonists act at incretin receptors; cagrilintide acts at the calcitonin receptor and the three amylin receptors, which are calcitonin-receptor heterodimers with RAMP proteins. That non-overlap is precisely why the two classes are studied in combination rather than as alternatives.
What should a COA for cagrilintide show?
Mass near 4409 Da by LC-MS, RP-HPLC purity, and — more informative than either for this molecule — some evidence bearing on disulfide pairing and aggregate content. A single purity percentage cannot distinguish correctly folded material from a disulfide-scrambled isomer of identical mass.
What Cagrilintide is studied for
Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.
A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.
The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.
The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021.
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025.
- Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025.
- Browse current Cagrilintide literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More Cagrilintide reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
FAQ reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
Cagrilintide is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.